Core Viewpoint - The company, Aipu Flavor Group Co., Ltd., has signed a Letter of Intent for Equity Acquisition with NovoSana (Europe) B.V. to acquire 100% equity of NovoSana (Taicang) Biotechnology Co., Ltd., with an estimated value of no less than RMB 450 million [3][11]. Group 1: Basic Information of the Agreement - The agreement aims to enhance the company's strategic layout and promote the extension of the industrial chain for high-quality development [5]. - The initial transaction involves the acquisition of 80% equity, with a second transaction planned after the performance commitment period [10][11]. - The estimated value of the target company's 100% equity is set at no less than RMB 450 million, with the final price to be determined through due diligence and negotiation [3][11]. Group 2: Financial and Operational Details - The target company, NovoSana (Taicang) Biotechnology Co., Ltd., specializes in the research, production, and sales of Omega-3 raw materials, including fish oil and algae oil [7]. - The target company has accumulated significant industry resources and has a client base that includes globally recognized health products and functional food companies [7]. - The financial status of the target company includes an estimated audited net profit of RMB 38 million for 2025 and total equity of RMB 148.64 million [12]. Group 3: Transaction Conditions and Obligations - The agreement stipulates that the buyer will pay a deposit of RMB 10 million within five working days after signing the Letter of Intent [15]. - The funding for the acquisition will come from the company's own or self-raised funds, ensuring no impact on normal operations [22]. - The agreement includes exclusivity clauses preventing the seller from engaging with third parties regarding the sale of the target company's equity until the transaction is completed [17].

Core Viewpoint - Aipu Co., Ltd. (603020.SH) has signed an equity acquisition intention agreement with Noah Sanno Europe to acquire 100% equity of Noah Sanno (Taicang) Biotechnology Co., Ltd. to enhance its strategic layout and achieve high-quality development [1] Group 1: Acquisition Details - The acquisition will occur in two phases: Aipu will first acquire 80% of the target company, followed by the remaining equity after the performance commitment period [1] - The transaction price will be determined based on due diligence, auditing, and valuation results, subject to negotiation between both parties [1] Group 2: Target Company Overview - The target company, established in 2009 and located in Taicang, Jiangsu, specializes in the research, production, and sales of Omega-3 raw materials, including fish oil and algae oil [1] - Its main products include refined fish oil and concentrated fish oil, and it has built a strong customer base comprising globally recognized health supplement, functional food and beverage, infant nutrition, and pet food clients [1]

Core Viewpoint - Aipu Co., Ltd. (603020.SH) has signed an equity acquisition intention agreement with Noah Sanno Europe to acquire 100% equity of Noah Sanno (Taicang) Biotechnology Co., Ltd. to enhance its strategic layout and achieve high-quality development [1] Group 1: Acquisition Details - The acquisition will occur in two phases: Aipu will first acquire 80% of the target company, followed by the remaining equity after the performance commitment period [1] - The final transaction price will be determined based on due diligence, auditing, and evaluation results, subject to negotiation between both parties [1] Group 2: Target Company Overview - The target company, established in 2009 and located in Taicang, Jiangsu, specializes in the research, production, and sales of Omega-3 raw materials, including fish oil and algae oil [1] - Its main products include refined fish oil and concentrated fish oil, and it has built a strong customer base comprising globally recognized health supplement, functional food and beverage, infant nutrition, and pet food clients [1]

Core Viewpoint - Aipu Spice Group Co., Ltd. plans to acquire 100% equity of NovoSana (Taicang) Biotechnology Co., Ltd. for a total valuation of no less than RMB 450 million, with the transaction structured in two phases [1][2]. Group 1: Acquisition Details - The first phase involves Aipu acquiring 80% of the equity for RMB 360 million, while the second phase will occur after the performance commitment period, acquiring the remaining 20% [1]. - The performance commitment period for the target company is set from 2026 to 2028, with a total net profit of no less than RMB 150 million expected during this period [1]. Group 2: Target Company Overview - NovoSana was established in 2007 with a registered capital of USD 5.1 million and is located in the Jiangsu Taicang Economic Development Zone [1]. - The company specializes in the development, production, and sales of food and food additives, particularly focusing on Omega-3 raw materials such as refined fish oil and concentrated fish oil [1]. - NovoSana's clients include globally recognized companies in health supplements, functional food and beverages, infant nutrition, and pet food sectors [1]. Group 3: Financial Projections - For the year 2024, NovoSana is projected to achieve a revenue of RMB 527 million and a net profit of RMB 48.24 million [1]. - The estimated revenue for 2025 is RMB 450 million, with an anticipated net profit of RMB 39.31 million (2025 data is unaudited) [1].